Please Wait.....
Report
Novo Nordisk A/S (NOVO B:CPH) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360? Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI?s, and Recent Trends
Company Report I 2025-02-27 I 116 Pages I Quaintel Research
Report Summary
Novo Nordisk A/S (NOVO B:CPH) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPIs, and Recent Trends Report is a comprehensive and easily accessible overview of Novo Nordisk A/S's business operations. It provides a detailed analysis of the company's financial and strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.
The report begins with in-depth information about Novo Nordisk A/S, including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.
Next, the report assesses Novo Nordisk A/S's strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. The PESTLE analysis evaluates the external factors impacting the company's operations and market environment. Additionally, By integrating these strategic analyses, the report offers a comprehensive understanding of Novo Nordisk A/S's overall strategic standing and supports informed decision-making and strategic planning.
The report also covers Novo Nordisk A/S's financial analysis basis of latest income statement, balance sheet, and cash flow statement. Key financial ratios related to profitability, asset turnover, credit, market, and long-term solvency are outlined, providing guidance for investment decisions. Furthermore, the report compares Novo Nordisk A/S's financial parameters with those of its competitors, offering a unique analysis of the competitive landscape. This information helps manage the business environment and improve sales activities by gaining insight into competitors' operations.
Finally, the report includes recent news and deal activities undertaken by Novo Nordisk A/S, enhancing awareness of the company's business trends, growth perspectives, and more.
Key Highlights
Novo Nordisk A/S operates as a healthcare company that engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. Novo Nordisk A/S operates in two main business segments - Diabetes and Obesity care, and Rare Disease. Novo Nordisk A/S offers products and services in the areas of diabetes care, obesity, rare blood disorders, growth disorders and hormone replacement therapy. It provides insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity treatments, haemophilia treatments, growth hormone therapy and hormone replacement therapy. Founded in 1923, the company is headquartered in Bagsvaerd, Copenhagen, Denmark.
Novo Nordisk A/S in the News:-
- 07-Feb-2025 - Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors
- 24-Jan-2025 - Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
- 17-Jan-2025 - Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
- 20-Dec-2024 - Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial
- 16-Dec-2024 - Novo Nordisk invests DKK 8.5 billion in new production facility in Odense, Denmark
Scope
Tactical Analysis:- Various strategic frameworks to gain insights into a company's competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
Business Strategy:- Contributes to shaping the company's overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
Financial Position:- Provide valuable information on the financial performance and investor sentiment surrounding the company. Indicating the level of confidence and expectations in the company's future prospects. These components collectively contribute to understanding the financial health and market perception of the company.
Company Fundamentals:- These fundamentals offer valuable insights into the company's history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
Competitive Landscape:- An identification of the company's main competitors, providing insights into the competitive landscape it operates in.
Reasons to Buy
Comprehensive Understanding of the Novo Nordisk A/S's internal and external factors through SWOT analysis, PESTLE analysis, Financial Analysis, and Competitors Benchmarking.
Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
Financial Performance Evaluation provides crucial insights into key financial ratios and trends, supporting better financial decision-making and resource allocation.
Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.
Additionally, available deep-dive analysis on the company Novo Nordisk A/S:
Novo Nordisk A/S Porter's Five Forces Analysis
Novo Nordisk A/S VRIO Analysis
Novo Nordisk A/S BCG Analysis
Novo Nordisk A/S Segmentation, Targeting and Positioning (STP) Analysis
Novo Nordisk A/S Ansoff Matrix Analysis
Table of Contents
COMPANY EXECUTIVE SUMMARY 1
Table of Contents 2
Tables 6
Charts 7
Novo Nordisk A/S - Key Company Facts 8
Novo Nordisk A/S - Company Description 9
Novo Nordisk A/S - Top Executives 10
Novo Nordisk A/S- Head Office & Locations 12
Head Office - Country 12
Novo Nordisk A/S - Products and Services 13
Products 13
Novo Nordisk A/S - Corporate Strategy 17
Novo Nordisk A/S - Business Description 23
Diabetes care 23
Obesity care 24
Rare Disease 24
Cardiovascular and Emerging Therapy Areas 25
Novo Nordisk A/S - ESG Spotlight 26
Environment 26
Social 27
Corporate Governance 27
Novo Nordisk A/S - SWOT Analysis 29
Overview 29
Strengths 31
Weaknesses 33
Opportunities 34
Threats 37
Novo Nordisk A/S PESTLE Analysis 39
Overview 39
Political Factors 41
Economic Factors 42
Social Factors 43
Technological Factors 44
Legal Factors 45
Environmental Factors 46
Novo Nordisk A/S - Financial Deep Dive 48
Share Price Trend - Feb-2024 to Feb-2025 (Average Share Closing Price) 48
Profit and Loss Statement 50
Summary of Profit and Loss Statement 50
Balance Sheet 52
Summary of Balance Sheet 52
Cash Flow Statement 54
Summary of Cash Flow Statement 54
Key Financial Ratio Analysis 56
Novo Nordisk A/S - Ratio Charts 57
Activity Ratio Charts 57
Growth Ratios Charts 58
Leverage Ratio Charts 59
Liquidity Ratio Charts 60
Profitability Ratio Charts 61
Competing Players 62
Snapshot of Competing Players 63
Johnson & Johnson 63
Key Company Facts 63
Company Description 63
Novartis AG 64
Key Company Facts 64
Company Description 64
Pfizer Inc. 65
Key Company Facts 65
Company Description 65
Merck & Co., Inc. 66
Key Company Facts 66
Company Description 66
F. Hoffmann-La Roche Ltd 67
Key Company Facts 67
Company Description 67
Novo Nordisk A/S - In the News 68
07-Feb-2025 - Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors 68
24-Jan-2025 - Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity 70
17-Jan-2025 - Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence 70
20-Dec-2024 - Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial 72
16-Dec-2024 - Novo Nordisk invests DKK 8.5 billion in new production facility in Odense, Denmark 73
12-Dec-2024 - Novo Nordisk A/S: European regulatory authority adopts positive opinion for an update of the Ozempic label to reflect risk reduction of kidney disease-related events 74
13-May-2024 - Novo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A in the Frontier 2 trial 74
02-May-2024 - Novo Nordisk's sales increased by 22% in Danish kroner and by 24% at constant exchange rates to DKK 65.3 billion in the first three months of 2024 77
26-Apr-2024 - Novo Nordisk A/S Total number of voting rights and share capital in Novo Nordisk A/S as of 26 April 2024 77
24-Apr-2024 - Novo Nordisk A/S Reduction of the share capital 78
21-Mar-2024 - Awiqli (once-weekly basal insulin icodec) recommended for approval for the treatment of diabetes by the European regulatory authorities 79
08-Mar-2024 - Wegovy approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease 80
05-Mar-2024 - Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial 82
31-Jan-2024 - Novo Nordisk's sales increased by 31% in Danish kroner and by 36% at constant exchange rates to DKK 232.3 billion in 2023 84
08-Jan-2024 - COMBINE 3 phase 3a trial successfully completed with once-weekly IcoSema demonstrating non-inferior reduction in HbA1c versus daily basal-bolus treatment (insulin glargine U100 and insulin aspart) in people with type 2 diabetes 84
02-Nov-2023 - Novo Nordisk's sales increased by 29% in Danish kroner and by 33% at constant exchange rates to DKK 166.4 billion in the first nine months of 2023 86
Novo Nordisk A/S - Key Deals 87
08-Jan-2025 - Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases 88
18-Dec-2024 - The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is completed 89
25-Mar-2024 - Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease 90
05-Feb-2024 - Novo Nordisk to acquire three fill-finish sites from Novo Holdings A/S in connection with the Catalent, Inc. transaction 92
04-Jan-2024 - Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases 94
23-Nov-2023 - Novo Nordisk invests more than 16 billion Danish kroner in expansion of production facilities in Chartres, France 97
10-Nov-2023 - Novo Nordisk invests more than 42 billion Danish kroner in expansion of manufacturing facilities in Kalundborg, Denmark 99
16-Oct-2023 - Novo Nordisk to acquire ocedurenone for uncontrolled hypertension from KBP Biosciences 100
25-Sep-2023 - Valo Health and Novo Nordisk to collaborate to discover and develop novel treatments for cardiometabolic diseases using human data and artificial intelligence 103
20-Sep-2023 - Novo Nordisk and UNICEF to extend joint initiative to prevent global childhood obesity 105
10-Aug-2023 - Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases 107
12-Jun-2023 - Novo Nordisk invests DKK 15.9 bn in expansion of manufacturing facilities in Hillerod, Denmark 108
Appendix 109
Definitions 109
SWOT Analysis 109
PESTLE Analysis 109
Value Chain Analysis 109
ESG Spotlight 109
Financial Deep Dive 109
Financial Ratios - 110
Activity Ratios 110
Growth Ratios 111
Leverage Ratios 112
Liquidity Ratios 113
Market Ratios 114
Profitability Ratios 114
Research Methodology 115
Disclaimer 116
Contact Us 116
Tables
Table 1: Novo Nordisk A/S - Company Facts
Table 2: Novo Nordisk A/S - Digital Presence
Table 3: Novo Nordisk A/S - Top Executives
Table 4: Novo Nordisk A/S - Products
Table 5: Novo Nordisk A/S - Share Price Trend - Feb-2024 to Feb-2025
Table 6: Novo Nordisk A/S - Ratio Analysis - 2019-2022
Table 7: Novo Nordisk A/S - Competing Players
Table 8: Competing Players - Johnson & Johnson - Key Company Facts
Table 9: Competing Players - Novartis AG - Key Company Facts
Table 10: Competing Players - Pfizer Inc. - Key Company Facts
Table 11: Competing Players - Merck & Co., Inc. - Key Company Facts
Table 12: Competing Players - F. Hoffmann-La Roche Ltd - Key Company Facts
Charts
Figure 1: Novo Nordisk A/S- SWOT Analysis
Figure 2: Novo Nordisk A/S - PESTLE Analysis
Figure 3: Novo Nordisk A/S - Average Share Price Trend - Feb-2024 to Feb-2025
Figure 4: Novo Nordisk A/S - Profit and Loss Statement - 2021-2024
Figure 5: Novo Nordisk A/S - Balance Sheet - 2021-2024
Figure 6: Novo Nordisk A/S - Cash Flow Statement 2021-2024
Figure 7: Novo Nordisk A/S - Activity Ratio Charts
Figure 8: Novo Nordisk A/S - Growth Ratio Charts (Value %)
Figure 9: Novo Nordisk A/S - Leverage Ratio Charts
Figure 10: Novo Nordisk A/S - Liquidity Ratio Charts
Figure 11: Novo Nordisk A/S - Profitability Ratio Charts (Value %)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security